Timney will succeed Clive Meanwell, M.D., Ph.D., who has been appointed by the board to serve as chief innovation officer.
Timney has over 25 years of biopharmaceutical industry experience in multi-national companies.
At Merck and Co (NYSE: MRK), Timney led organisations of increasing importance and size, including president US, president Japan and president of Global Primary Care.
In these roles, Timney launched multiple products, many in the cardiovascular therapeutic area, led large organisations of up to 8,000 employees, and was involved in a number of important strategic transactions.
After leaving Merck, Timney served as the CEO of Purdue Pharmaceuticals and formed a company advising healthcare companies.
Before joining Merck, Timney spent eight years working at numerous multinational pharmaceutical companies, including Zeneca Group, ICI Pharmaceuticals and Roussel Labs.
The Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare.
The company's goal is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in cardiovascular care. The company is headquartered in Parsippany, New Jersey.
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Enable Biosciences names new chief financial officer
Cadenza Bio names new director
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation